Lobular carcinoma in situ of right breast
ICD-10 D05.01 is a billable code used to indicate a diagnosis of lobular carcinoma in situ of right breast.
Lobular carcinoma in situ (LCIS) of the right breast is a non-invasive form of breast cancer characterized by the proliferation of atypical lobular cells within the lobules of the breast. Unlike invasive breast cancer, LCIS does not invade surrounding breast tissue or metastasize to other parts of the body. However, it is considered a marker for increased risk of developing invasive breast cancer in either breast in the future. Patients diagnosed with LCIS often undergo regular surveillance, including clinical breast exams and imaging studies such as mammograms or MRIs, to monitor for any changes. The diagnosis of LCIS is typically made through a biopsy, and it is essential for healthcare providers to differentiate it from other breast lesions, as the management and follow-up protocols differ significantly. While LCIS itself is not life-threatening, its presence necessitates careful monitoring and may lead to discussions about preventive measures, including chemoprevention or prophylactic mastectomy, depending on individual risk factors and patient preferences.
Detailed pathology reports, imaging results, and treatment plans.
Diagnosis of LCIS during routine screening, management of patients with a family history of breast cancer.
Ensure accurate staging and follow-up plans are documented.
Imaging reports that clearly indicate findings related to LCIS.
Mammography or MRI follow-ups for patients with a history of LCIS.
Documentation must specify the reason for imaging and any findings related to LCIS.
Used for surveillance in patients with a history of LCIS.
Indication for MRI and previous imaging results.
Radiologists should document findings related to LCIS.
Lobular carcinoma in situ (LCIS) is a non-invasive breast condition where abnormal cells are found in the lobules of the breast. It is not considered breast cancer but indicates an increased risk for developing invasive breast cancer in the future.
LCIS is typically diagnosed through a biopsy, often following an abnormal mammogram or clinical examination. Pathological evaluation reveals atypical lobular cells.
Treatment options for LCIS may include increased surveillance, chemoprevention with medications like tamoxifen, or prophylactic mastectomy, depending on individual risk factors and patient preferences.
